ATE466028T1 - N-terminal veränderte glp-1 abkömmlinge - Google Patents
N-terminal veränderte glp-1 abkömmlingeInfo
- Publication number
- ATE466028T1 ATE466028T1 AT99906078T AT99906078T ATE466028T1 AT E466028 T1 ATE466028 T1 AT E466028T1 AT 99906078 T AT99906078 T AT 99906078T AT 99906078 T AT99906078 T AT 99906078T AT E466028 T1 ATE466028 T1 AT E466028T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- glp
- terminally modified
- insulin dependent
- modified glp
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK26398 | 1998-02-27 | ||
| DK26898 | 1998-02-27 | ||
| DK50898 | 1998-04-08 | ||
| PCT/DK1999/000085 WO1999043707A1 (en) | 1998-02-27 | 1999-02-25 | N-terminally modified glp-1 derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466028T1 true ATE466028T1 (de) | 2010-05-15 |
Family
ID=27220551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99906078T ATE466028T1 (de) | 1998-02-27 | 1999-02-25 | N-terminal veränderte glp-1 abkömmlinge |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1062240B1 (de) |
| JP (1) | JP2002506792A (de) |
| AT (1) | ATE466028T1 (de) |
| AU (1) | AU2610899A (de) |
| DE (1) | DE69942307D1 (de) |
| WO (1) | WO1999043707A1 (de) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| EP1100530B1 (de) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation von beta zellen vermehrung |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (de) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
| EP1263458B1 (de) | 2000-03-08 | 2005-11-16 | Novo Nordisk A/S | Senkung des serum cholesterols |
| JP2003526671A (ja) * | 2000-03-14 | 2003-09-09 | レストラゲン，インコーポレイテッド | 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用 |
| CN1454214A (zh) * | 2000-08-02 | 2003-11-05 | 赛莱技术公司 | 具有增高功效的修饰生物肽 |
| DE60136958D1 (de) | 2000-12-01 | 2009-01-22 | Takeda Pharmaceutical | Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz |
| WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| JP4227894B2 (ja) * | 2001-08-23 | 2009-02-18 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド１アナログ |
| WO2003020201A2 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| CN100350968C (zh) | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
| CA2463803A1 (en) * | 2001-10-19 | 2003-05-01 | Eli Lilly And Company | Biphasic mixtures of glp-1 and insulin |
| EP1585959A4 (de) | 2002-01-08 | 2007-11-14 | Lilly Co Eli | Verlängerte analoge des glucagonähnlichen peptids 1 |
| JP4733922B2 (ja) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | 摂食行動の修正 |
| AU2003273300A1 (en) * | 2002-09-06 | 2004-03-29 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| CA2500021A1 (en) | 2002-09-25 | 2004-04-08 | Theratechnologies Inc. | Modified glp-1 peptides with increased biological potency |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US20050059605A1 (en) * | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| WO2004078777A2 (en) * | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| US7259234B2 (en) | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| EP1633391B1 (de) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilisierte pharmazeutische peptid zusammensetzungen |
| KR101308912B1 (ko) | 2003-06-03 | 2013-09-23 | 노보 노르디스크 에이/에스 | 안정화된 약학적 펩티드 조성물 |
| RU2401276C2 (ru) * | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| EP1667724A2 (de) * | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin bindende derivate von therapeutischen peptiden |
| CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| MXPA06002941A (es) * | 2003-09-19 | 2006-05-31 | Novo Nordisk As | Derivados de enlace a albumina de peptidos terapeuticos. |
| EP1687019B1 (de) | 2003-11-20 | 2017-11-22 | Novo Nordisk A/S | Für die herstellung und verwendung in injektionsvorrichtungen optimale propylenglykol enhaltende peptidformulierungen |
| EP2298337B1 (de) | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten |
| EP2210900A3 (de) * | 2003-12-16 | 2010-08-11 | Ipsen Pharma | GlLP-1-Analoga |
| JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和 |
| PL1789434T3 (pl) | 2004-08-31 | 2014-07-31 | Novo Nordisk As | Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek |
| EP2494983B1 (de) | 2004-11-12 | 2019-04-24 | Novo Nordisk A/S | Stabile formulierung von glp-1 |
| KR20070120112A (ko) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | 연장형 ｇｌｐ-1 화합물 |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP2008539735A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法 |
| ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
| KR101193722B1 (ko) | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | 엑센딘 융합 단백질 |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| KR20110122100A (ko) | 2009-01-22 | 2011-11-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 안정한 성장 호르몬 화합물 |
| JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| US8648041B2 (en) * | 2009-12-16 | 2014-02-11 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| CN106139158B (zh) | 2010-01-22 | 2024-06-21 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
| AU2011247452B2 (en) | 2010-04-27 | 2016-03-17 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
| WO2011136361A1 (ja) | 2010-04-30 | 2011-11-03 | 株式会社 三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| PT2651398T (pt) | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
| MX2014005351A (es) | 2011-11-03 | 2014-05-28 | Zealand Pharma As | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. |
| SI2827845T1 (sl) | 2012-03-22 | 2019-04-30 | Novo Nordisk A/S | Sestavki, ki obsegajo dostavno sredstvo in njihova priprava |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| HUE062740T2 (hu) | 2012-03-22 | 2023-12-28 | Novo Nordisk As | GLP-1 peptidek készítményei és elõállításuk |
| EP2863895B1 (de) | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler |
| EP2873422A4 (de) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | Pharmazeutische zubereitung zur injektion |
| JP6534927B2 (ja) | 2012-07-23 | 2019-06-26 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014060472A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| EP2981282B1 (de) | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Wachstumshormonverbindungsformulierung |
| US20160067184A1 (en) | 2013-05-02 | 2016-03-10 | Novo Nordisk A/S | Oral Dosing of GLP-1 Compounds |
| PE20160683A1 (es) | 2013-10-17 | 2016-07-21 | Zealand Pharma As | Analogos de glucagon acilados |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| EP3006045B3 (de) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln |
| ES2883345T3 (es) | 2014-10-29 | 2021-12-07 | Zealand Pharma As | Compuestos agonistas del GIP y métodos |
| AU2016247499B2 (en) | 2015-04-16 | 2020-09-03 | Zealand Pharma A/S | Acylated glucagon analogue |
| JP2018529749A (ja) | 2015-10-07 | 2018-10-11 | シプルメット・ゲーエムベーハー | ペプチド薬物を経口送達するための医薬製剤 |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
| CA3082033A1 (en) | 2017-08-24 | 2019-02-28 | Novo Nordisk A\S | Glp-1 compositions and uses thereof |
| KR102647171B1 (ko) | 2018-02-02 | 2024-03-15 | 노보 노르디스크 에이/에스 | Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물 |
| IL277495B2 (en) * | 2018-03-23 | 2024-08-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
| DK4122954T3 (da) | 2018-04-05 | 2024-06-10 | Sun Pharmaceutical Ind Ltd | Novel GLP-1-analoger |
| EP3773475A1 (de) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmazeutische zusammensetzungen zur transmukosalen abgabe von therapeutischen peptiden und proteinen |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
| WO2021219710A1 (en) | 2020-04-29 | 2021-11-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
| CN116419750A (zh) | 2020-09-07 | 2023-07-11 | 西普鲁梅有限公司 | 改进的glp-1受体激动剂的药物制剂 |
| JP2023545684A (ja) | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| MX2023013492A (es) | 2021-05-13 | 2024-02-29 | Carmot Therapeutics Inc | Moduladores de los receptores acoplados a proteinas g. |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| CN116848243B (zh) | 2022-03-30 | 2024-03-19 | 北京质肽生物医药科技有限公司 | 多肽缀合物的液体药物组合物和其使用方法 |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (de) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitoren der expression und/oder funktion |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| EP0305387B2 (de) | 1986-05-05 | 1996-08-28 | The General Hospital Corporation | Insulinotropes hormon |
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| WO1990011296A1 (en) | 1989-03-20 | 1990-10-04 | The General Hospital Corporation | Insulinotropic hormone |
| DK0512042T3 (da) | 1990-01-24 | 1998-05-11 | Douglas I Buckley | GLP-1-analoger anvendelige ved diabetesbehandling |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DK1975177T3 (da) * | 1996-03-01 | 2011-07-25 | Novo Nordisk As | Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf |
| HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
-
1999
- 1999-02-25 WO PCT/DK1999/000085 patent/WO1999043707A1/en not_active Ceased
- 1999-02-25 AT AT99906078T patent/ATE466028T1/de not_active IP Right Cessation
- 1999-02-25 EP EP99906078A patent/EP1062240B1/de not_active Expired - Lifetime
- 1999-02-25 JP JP2000533457A patent/JP2002506792A/ja active Pending
- 1999-02-25 DE DE69942307T patent/DE69942307D1/de not_active Expired - Lifetime
- 1999-02-25 AU AU26108/99A patent/AU2610899A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002506792A (ja) | 2002-03-05 |
| AU2610899A (en) | 1999-09-15 |
| EP1062240B1 (de) | 2010-04-28 |
| WO1999043707A1 (en) | 1999-09-02 |
| EP1062240A1 (de) | 2000-12-27 |
| DE69942307D1 (de) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE466028T1 (de) | N-terminal veränderte glp-1 abkömmlinge | |
| WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
| ATE193541T1 (de) | Insulinotropes hormon | |
| NO954055L (no) | Glukogen-liknende insulintropiske peptidanaloger, sammensetninger og fremgangsmåter for anvendelse derav | |
| Deacon | Circulation and degradation of GIP and GLP-1 | |
| PH12021550154A1 (en) | Gip/glp1 co-agonist compounds. | |
| MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
| US20050137135A1 (en) | Novel analogues of glucose-dependent insulinotropic polypeptide | |
| WO2006121860A3 (en) | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use | |
| DE69531889D1 (de) | Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides | |
| NO992557L (no) | Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme | |
| DE69327309D1 (de) | Verwendung eines peptids | |
| EP2070946A3 (de) | Erfindung betreffend GLP-1 und Exendin | |
| EA199900169A1 (ru) | Применение глюкагоноподобного пептида-1 (glp-1) или его аналогов для устранения катаболических изменений после оперативного вмешательства | |
| CO5090908A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
| CA2909581A1 (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| NZ515902A (en) | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes | |
| GEP20063908B (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
| CY1106971T1 (el) | Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης | |
| WO2000077039A3 (en) | Glp-1 as a diagnostic test to determine beta-cell function | |
| BR0212080A (pt) | composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1 | |
| JP2012512903A5 (de) | ||
| DK1094834T3 (da) | Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf | |
| ZA200606153B (en) | Intranasal administration of glucose-regulating peptides | |
| BR0308904A (pt) | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |